Best Healthcare Stocks to Buy After the Market Pullback

Medicare Advantage proposed payment rates for 2027 rise just 0.09% year-over-year, creating margin pressure for CVS Health and contributing to a Q4 post-earnings sell-off driven by rising costs. CVS's diversified retail footprint and plan to scale back less-profitable MA operations are presented as mitigants, supporting a cautious long-term buy case. AbbVie expects Skyrizi and Rinvoq to combine for more than $31 billion in sales this year, which management says more than offsets Humira's decline, and a deep pipeline (e.g., emraclidine) plus 54 consecutive years of dividend increases underpin an income-oriented buy-and-hold thesis.

Analysis

CVS: the most important lever management can pull is shifting revenue mix away from reimbursement-exposed MA lives and toward higher-margin, point-of-care services embedded in its retail footprint. That shift has second-order effects: smaller independent clinics and local health systems will see increased referral flow (or competitive pressure), pharmacy wholesale volumes and formularly volumes could compress, and real-estate optimization (store-to-clinic conversions or selective closures) becomes a meaningful P&L lever rather than a mere cost cut. Expect margin relief to come incrementally over 6–18 months as new service lines scale and contract renegotiations with PBM/plan partners complete.

AbbVie: the company’s optionality is now a function of launch execution and international price mix rather than a single patent timetable. Successful label expansions or new indications will lever existing specialty sales infrastructure and drive margin expansion faster than greenfield launches because distribution and payer relationships are already in place. The primary risk is adoption timing—revenue profiles hinge on 2–4 quarter adoption curves and payer formulary placements; a modest miss in conversion rates or tender outcomes can shave high-single-digit percentage points off expected growth in a single year.

Macro/risk framing: regulatory/pricing headlines and quarterly enrollment trends are the highest-probability catalysts in the next 3–12 months; biosimilar penetration and trial readouts are multi-year convexity events. Position sizing should reflect binary outcomes—near-term volatility from reimbursement decisions can exceed 15% for either stock but long-term directional payoffs are tied to execution on margin mix (CVS) and durable specialty adoption + pipeline approvals (AbbVie).

Key Decisions for Investors

• Pair trade (12–18 months): Long ABBV equity (or buy a 12–18 month call spread to cap premium) / Short CVS equity equal-dollar. Rationale: capture relative upside from specialty adoption and dividend carry versus downside from insurance-margin compression. Risk: if broad healthcare rehospitalization or enrollment beats expectations, spread could compress; target asymmetric payoff of 1.5–3x upside vs max loss = 100% of option premium or stock move against position.
• CVS hedge (3–9 months): Buy protective put spread on CVS (buy 6–9 month put, sell cheaper put) sized to cover 20–30% of equity exposure. Rationale: insulates against near-term reimbursement/regulatory shocks while keeping cost contained. Risk/reward: cost ~1–3% of notional for 20–30% protection; breakeven if headline-driven drawdown > protection cost.
• AbbVie income-plus (12 months): Buy ABBV and overlay a staggered covered-call ladder (3–9 month expiries) to capture dividend plus premium while keeping upside optionality. Rationale: collects yield and reduces effective entry; if pipeline/launch news is positive, rolling calls preserves exposure. Risk: capping upside vs equity rally; effective yield enhancement 2–4% annualized depending on strike selection.
• Event short catalyst (6–12 months): Small tactical short on specialized retail/independent pharmacy suppliers benefiting from volume concentration if CVS continues to de-risk MA book — size <5% book. Rationale: lower guaranteed volumes and contracting leverage compress supplier margins. Risk: mis-timing of contract renewals or competitor disruption that preserves supplier volume.